The estimated Net Worth of Theodore James Jr. Washburn is at least $335 Mille dollars as of 3 June 2024. Theodore Washburn owns over 1,362 units of Agios Pharmaceuticals Inc stock worth over $67,528 and over the last 3 years Theodore sold AGIO stock worth over $267,867.
Theodore has made over 17 trades of the Agios Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Theodore sold 1,362 units of AGIO stock worth $60,459 on 3 June 2024.
The largest trade Theodore's ever made was exercising 4,150 units of Agios Pharmaceuticals Inc stock on 1 August 2023 worth over $183,887. On average, Theodore trades about 1,074 units every 47 days since 2022. As of 3 June 2024 Theodore still owns at least 1,524 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Theodore Washburn stock trades at the bottom of the page.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen e John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: